Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax Monotherapy and in Combination With Ruxolitinib in MPN
NCT04041050Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 1, open-label trial of navitoclax in myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), sponsored by AbbVie Inc. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Observed Plasma Concentration of Navitoclax at 1 day and 7 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04041050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041050.